Výsledky vyhledávání - "Ryan Overland"

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Autor: Violette Paragas, Matt Wallace, Stephanie Nguyen, Ryan Overland, Michael Feldhaus, Neeraj Kohli, Lia Luus, Brian Harms, Birgit Schoeberl, Bo Zhang, Aruthur J Kudla, Sharlene Adams, Ulrik B. Nielsen, Charlotte Mcdonagh, Shinji Oyama, Jinming Gu, Alexandra Huhalov

Publikováno v: Molecular Cancer Therapeutics. 11:582-593

The prevalence of ErbB2 amplification in breast cancer has resulted in the heavy pursuit of ErbB2 as a therapeutic target. Although both the ErbB2 monoclonal antibody trastuzumab and ErbB1/ErbB2 dual kinase inhibitor lapatinib have met with success i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::648bfc7fca06202d74d2520d4e983bab
https://doi.org/10.1158/1535-7163.mct-11-0820

Zobrazit plný text záznamu

Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors

Autor: Emily Pace, Matthew Onsum, Violette Paragas, Johanna Lahdenranta, Ulrik B. Nielsen, Charlotte Mcdonagh, Daniel C. Kirouac, Ryan Overland, Defne Yarar, Jin Y. Du

Publikováno v: Science signaling. 6(288)

Crosstalk and compensatory circuits within cancer signaling networks limit the activity of most targeted therapies. For example, altered signaling in the networks activated by the ErbB family of receptors, particularly in ERBB2-amplified cancers, con

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65e13e6d85a26b8a9beb896165e447d7
https://pubmed.ncbi.nlm.nih.gov/23943608

Zobrazit plný text záznamu

Abstract A10: In silico design of biomarker-optimized drug combinations in ERBB2+ cancers

Autor: Daniel C. Kirouac, Matthew Onsum, Ryan Overland, Charlotte Mcdonagh, Jinyan Du, Johanna Lahdenranta

Publikováno v: Cancer Research. 73:A10-A10

Crosstalk and compensatory circuits within cancer signaling networks fundamentally limit the activity of targeted therapies. Combination drug regimens are thus required to fully inhibit an oncogenic network. However, rationally designing optimal comb

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::288f5274ab2063b0a8d9a7ee7b0499a8
https://doi.org/10.1158/1538-7445.fbcr13-a10

Zobrazit plný text záznamu

Abstract 4633: MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer

Autor: Stephanie Nguyen, Violette Paragas, Daniel C. Kirouac, Johanna Lahdenranta, Bo Zhang, Matthew Onsum, Charlotte Mcdonagh, Ryan Overland, Ulrik B. Nielsen, Arthur J. Kudla, Jinyan Du

Publikováno v: Cancer Research. 73:4633-4633

Increasing evidence suggests amplification or overexpression of human epidermal growth factor receptor-2 (HER2), and HER3 levels are correlated to decreased survival in gastric cancers. Our previous studies established that MM-111, a novel bispecific

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42dcf8cb90bd2cbfd0b8a5957f004378
https://doi.org/10.1158/1538-7445.am2013-4633

Zobrazit plný text záznamu

Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB2-positive gastric and gastroesophageal junction cancer

Autor: Violette Paragas, Matthew Onsum, Johanna Lahdenranta, Victor Moyo, Arthur J. Kudla, Charlotte Mcdonagh, Ulrik B. Nielsen, Ryan Overland

Publikováno v: Journal of Clinical Oncology. 31:48-48

48 Background: ErbB2 (HER2) overexpression has been reported in 7-34% of gastric cancers. ErbB3 (HER3) is the preferred dimerization partner of ErbB2, and ErbB2/ErbB3 heterodimer activation is implicated in the progression and metastasis of ErbB2+ tu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0b127a59db224aab30eb9b4c0f643e12
https://doi.org/10.1200/jco.2013.31.4_suppl.48

Zobrazit plný text záznamu

Abstract A8: Combating adaptive ERBB3-mediated resistance to ERBB2 inhibitors: In Silico optimization of MM-111 and lapatinib dosing regimens

Autor: Mathew Onsum, Daniel C. Kirouac, Ulrik Nielson, Johanna Lahdenranta, Jinyan Du, Charlotte Mcdonagh, Ryan Overland

Publikováno v: Clinical Cancer Research. 18:A8-A8

Upregulation of ErbB3 (HER3) signaling has been implicated as a resistance mechanism to targeted ErbB1 and ErbB2 (HER1/2) inhibitors, limiting the efficacy of drugs such as lapatinib (Tykerb®), gefitinib (Iressa©), cetuximab (Erbitux®), and trastu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46aa9564d54fef9b917b672abd34cafd
https://doi.org/10.1158/1078-0432.mechres-a8

Zobrazit plný text záznamu

Abstract 654: MM-111, an ErbB2/ErbB3 bispecific antibody, effectively combines with lapatinib to inhibit growth of ErbB2-overexpressing tumor cells

Autor: Arthur J. Kudla, Shinji Oyama, Ryan Overland, Charlotte Mcdonagh, Clet Niyikiza, Violette Paragas, Gavin MacBeath, Lia Luus, Sharlene Adams, Ulrik B. Nielsen, Alexandra Huhalov

Publikováno v: Cancer Research. 71:654-654

The oncogenic receptor ErbB2 (HER2) is frequently overexpressed in a variety of cancer indications, including breast, gastric, bladder, and lung. ErbB3 (HER3), the preferred dimerization partner of ErbB2, is critical for the survival and growth of Er

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::906eca4afaa8809f483e7e3c1072b987
https://doi.org/10.1158/1538-7445.am2011-654

Zobrazit plný text záznamu

Abstract 655: Combination of MM-111, an ErbB2/ErbB3 bispecific antibody, with endocrine therapies as an effective strategy for treatment of ER+/HER2+ breast cancer

Autor: Gavin MacBeath, Olga Burenkova, Arthur J. Kudla, Clet Niyikiza, Stephanie Nguyen, Sharlene Adams, Ulrik B. Nielsen, Charlotte Mcdonagh, Bo Zhang, Ryan Overland, Alexandra Huhalov

Publikováno v: Cancer Research. 71:655-655

Approximately 75% of breast cancers are estrogen receptor (ER) positive. Although endocrine therapies such as tamoxifen, fulvestrant, and letrozole have demonstrated significant efficacy in treating ER+ breast cancer patients, intrinsic or acquired r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cbc60f8e77bab2e74d137847987ec17e
https://doi.org/10.1158/1538-7445.am2011-655

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání